Gain Therapeutics, Inc.

Print
General Information
Business:
We are a development-stage biotechnology company developing novel therapeutics to treat rare genetic diseases and neurological disorders caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”). We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. While the SEE-Tx platform is novel and has not been used to develop approved drugs yet, these advantages have the potential to ultimately enhance both tolerability and response.
 
As of Feb. 19, 2021, we have filed three patent applications and one provisional patent application (such applications do not cover the United States) for our novel Structurally Targeted Allosteric Regulators (“STARs”), which are small molecules with the potential to treat diseases with high unmet medical need for which there arefew or no available therapies. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.
 
Industry: Pharmaceuticals
Employees: 14
Founded: 2017
Contact Information
Address 4800 Hampden Lane, Suite 200 Bethesda, MD 20814
Phone Number (301) 500-1556
Web Address
View Prospectus: Gain Therapeutics, Inc.
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-3.58 mil (last 12 months)
IPO Profile
Symbol GANX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $40.0 mil
Manager / Joint Managers BTIG/Oppenheimer & Co.
CO-Managers National Securities
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change